Tumour Lysis Syndrome One of the oncologic emergencies most feared by oncologists, hematologists, and of course nephrologists👇 nature.com/articles/s4157…

Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer 💥An excellent review👇 nature.com/articles/s4157…

Why do cancer cells prefer the anaerobic glycolysis pathway? Could the answer be increased lactate production? 🔍Recent discoveries about the effects of lactate on DNA repair mechanisms and chemotherapy resistance👇 nature nature.com/articles/d4158…

mRNA akciğer kanseri aşısı Türkiye dahil, 7 ülkede, araştırma aşamasında! Başarılı olursa, kanser tedavisinde devrim yaratabilir. Peki, aşı karşıtları buna da karşı çıkacak mı? #Cancer #bilim #Oncology

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development annalsofoncology.org/article/S0923-…

My Top 10 Breast Cancer Abstracts list at #ESMO24 👇

Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor–Positive Breast Cancer: ASCO Guideline Clinical Insights Expert recommendations for problems encountered in clinical practice👇 ascopubs.org/doi/10.1200/OP…

Renal Cell Carcinoma jamanetwork.com/journals/jama/…

My Top 10 Gastrointestinal Cancer Abstracts #ESMO24 ESMO - Eur. Oncology

#Hematology: This is the #algorithm we’ve used during our 🗣️ w/ Jorge Cortes MD on #CML. Do you use #Imatinib in most of your pts or 2nd Gen TKIs upfront? If/once approved, are you going to use #Asciminib in most? #OncTwitter #MedTwitter #HemeTwitter CancerNetwork® OncoAlert #leusm

Neoadjuvant ICIs in Early BC: meta-analysis ✅️Neoadj ICIs increase pCR rates in both TNBC and HR+/HER2- (PDL1+) subtypes ✅️Neoadj ICI is associated with EFS regardless of pCR status ❗️Adjuvant ICI provides no additional benefit 🔍The results of OptimICE-PCR will provide

Our new article is out Scientific Reports 📢📢 We evaluated the WNT and TGF-B alterations in Young-Onset CRC ‼️ ☑️Similar rate of mutations in the WNT pathway ↔️↔️ ☑️Lower rate of mutations in the TGF-B pathway in the Young-Onset CRC ⬇️⬇️ ☑️Higher median TMB in Young-Onset CRC⬆️⬆️

Real-world overall survival after alternative dosing for pembrolizumab in the treatment of NCSLC 💥In this RWD involving 1996 patients, low-dose pembrolizumab significantly reduces costs without compromising efficacy lungcancerjournal.info/article/S0169-…

A must-read nature Editorial: What do local or vulnerable populations gain from being included in research studies? Are these studies ethical if they do not benefit the participants in any way but bring material or moral gains to others? Is this a form of biological theft?

☠️In 2030, almost %25 of rectal cancers will be young-onset. 👉Early-onset CRCs are mostly not hereditary! 👉Disrupted microbiota is key! ❓We use aggressive treatments, but is the biological behavior similar to traditional CRC? Cihangir Akyol, MD Yakup Ergün Eda Eylemer Mocan

A peer review invitation from an open-access journal: If, as a result of the peer review, the article is accepted, a reviewer fee of between $10 and $50 will be paid, depending on the quality of the review report. If the article is not accepted, no fee will be paid, and the

Oxaliplatin Addition to Adjuvant ChT in High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis 💥In high-risk stage II CC, adding oxaliplatin to FP does not provide any benefit in terms of OS ❗️An analysis based on MSI status and T4a/b was not performed

Management of Locally Advanced Rectal Cancer: ASCO Guideline Clinical Insights 📌The article addresses the challenges clinicians may face in applying the ASCO guidelines for the management of locally advanced rectal cancer ascopubs.org/doi/10.1200/OP…

Omission of 5-FU Bolus From Multidrug Regimens 🔍Retrospective study with ~12,000 pts in GI cancer 💥Omitting 5-FU bolus had no negative impact on survival (FOLFOX, FOLFIRI, FOLFIRINOX) 💥Associated with a significant reduction in toxicity jnccn.org/view/journals/…